Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Middle area:

Key facts & figures

Sanofi is an integrated global healthcare company focused on patient needs. Our business includes pharmaceuticals (prescription drugs, consumer healthcare and generics), vaccines and animal health.

The creation of growth platforms and the evolution of our R&D pipeline have effectively transformed Sanofi into a major biopharmaceutical player.

FY 2013 Net Sales

€32,951m

-0.5% at constant exchange rates
-5.7% on a reported basis

 

FY 2013 Business EPS

€5.05

-9.8% at constant exchange rates
-17,8% on a reported basis

 

Growth Platforms in 2013

€23,905m

+6.6% at constant exchange rates
Accounted for 72.5% of total sales in 2013

 

Emerging Markets: Sanofi is the #1 healthcare company in Emerging Markets with a broad product portfolio adapted to local needs.

Diabetes Solutions: Lantus®, our basal insulin, is the world’s leading diabetes brand.

Human Vaccines: Sanofi Pasteur offers a broad range of vaccines against 20 serious diseases and is the undisputed leader in flu vaccines.

Consumer Healthcare (CHC): Sanofi is the world's 3rd largest CHC player.

Genzyme: a leader in biotechnology, is our global center for excellence in rare diseases and multiple sclerosis.

Animal Health: Merial is a global leader in Animal Health with expertise in both veterinary pharmaceutical products and vaccines.

Other Innovative Products: On April 29, 2014, the R&D portfolio included 50 projects, 12 of which were in Phase III or had been submitted for approval.

Sales of Growth Platforms in 2013
FY 2013 salesGrowth at CER
Emerging Markets*€10,957m+4.4%
Diabetes Solutions€6,568m+18.7%
Vaccines€3,716m-0.1%
Consumer Healthcare€3,004m+5.2%
Genzyme€2,142m+25.9%
Animal Health€1,985m-5.3%
Other Innovative Products**€705m+18.8%

* World excluding U.S., Canada, Western Europe, Japan, Australia, and New Zealand
**
Products launched since 2009 which are not included in the Growth Platforms listed above: Multaq®, Jevtana®, Auvi-Q™, Mozobil® and Zaltrap®

 

Right area:

Stock Market

IR mobile application

Download IR Application

SANOFI IR is available on iPhone, iPad and Android!

 

IFRIC 21

New interpretation of tax levies - applicable as from January 1st, 2014

 

IAS19R

Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013

 
 

© Sanofi 2004-2014 - All rights reserved - Update: October 10, 2014

  • Site complies with W3C WCAG 2.0 (new window, in english)